4.7 Article

Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

期刊

CLINICAL CANCER RESEARCH
卷 19, 期 5, 页码 1139-1146

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-12-2127

关键词

-

类别

资金

  1. NIH [CA130938, CA62924, CA122581]
  2. Sol Goldman Pancreatic Cancer Research Center
  3. Stewart Trust Fund
  4. Lustgarten Foundation
  5. Mary Lou Wootton Pancreatic Cancer Research Fund
  6. Michael Rolfe Pancreatic Cancer Foundation
  7. HERA Foundation

向作者/读者索取更多资源

Purpose: High-throughput chemosensitivity testing of low-passage cancer cell lines can be used to prioritize agents for personalized chemotherapy. However, generating cell lines from primary cancers is difficult because contaminating stromal cells overgrow the malignant cells. Experimental Design: We produced a series of hypoxanthine phosphoribosyl transferase (hprt)-null immunodeficient mice. During growth of human cancers in these mice, hprt-null murine stromal cells replace their human counterparts. Results: Pancreatic and ovarian cancers explanted from these mice were grown in selection media to produce pure human cancer cell lines. Wescreened one cell line with a 3,131-drug panel and identified 77 U.S. Food and Drug Administration (FDA)-approved drugs with activity, and two novel drugs to which the cell line was uniquely sensitive. Xenografts of this carcinoma were selectively responsive to both drugs. Conclusion: Chemotherapy can be personalized using patient-specific cell lines derived in biochemically selectable mice. Clin Cancer Res; 19(5); 1139-46. (C) 2012 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据